A pilot study of quetiapine treatment of aggression due to traumatic brain injury

J Neuropsychiatry Clin Neurosci. Fall 2006;18(4):547-9. doi: 10.1176/jnp.2006.18.4.547.


In a 6-week open-label, flexible dose pilot study of quetiapine for treatment of aggression secondary to traumatic brain injury (TBI), seven subjects who were at least 3-months post-injury were enrolled. The Overt Aggression Scale - Modified (OAS-M) and Clinical Global Impression (CGI) were primary outcome measures. Administration of quetiapine at doses of 25 to 300 mg daily was efficacious and well-tolerated in reducing irritability and aggression resulting from TBI, with an associated improvement in cognitive functioning.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aggression / drug effects*
  • Antipsychotic Agents / therapeutic use*
  • Brain Injuries / drug therapy*
  • Brain Injuries / physiopathology
  • Cognition / drug effects
  • Dibenzothiazepines / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care / methods
  • Pilot Projects
  • Quetiapine Fumarate


  • Antipsychotic Agents
  • Dibenzothiazepines
  • Quetiapine Fumarate